Pyridoxine dependent epilepsy (PDE) (MIM#266100) is an autosomal recessive epileptic encephalopathy characterised by a therapeutic response to vitamin B 6 . Recently, deficiency in Antiquitin, a protein involved in the catabolism of lysine encoded by the ALDH7A1 gene has been identified as the underlying genetic cause.
CASE REPORT
Patient 1: was born to non-consanguineous Caucasian parents, by emergency C-section due to fetal deceleration. Her birth weight was 3.9 kg (75th centile) and the head circumference was 35 cm (50th centile). Apgar scores were 9 and 9 at one and five minutes. At 30 hours of life she had a generalized tonic-clonic status epilepticus with burst suppression pattern, along with high blood lactate concentrations (5.2 mmol/l; normal < 2.5). Seizures were unresponsive to phenytoin and phenobarbital. Seizures stopped clinically and electroencephalographically after intravenous pyridoxine (100mg) and thiamine (100 mg) administration and blood lactate concentrations normalized. Pyridoxine was given according to routine protocol in cases with pharmacologically intractable epilepsy. thiamine was given because pyruvate dehydrogenase (E1) deficiency, which is responsive to pharmacological dosages of thiamine, was considered as one possible differential diagnosis of lactic acidemia. Computed tomography (Ct) scan was normal. treatment was continued with pyridoxine and thiamine, as well as carbamazepine and phenytoin throughout adulthood. Her psychomotor development including speech was delayed (table) . She remained seizure free until the age of 19 years when seizures recurred but seizure control was regained when her medication doses were adjusted for her weight. Currently she is maintained on pyridoxine 400 mg, phenytoin 300 mg once daily, and carbamazepine 400 mg in the morning and 500 mg in the evening.
At the age of 23 years she has decreased muscle tone with reflexes +1, and a wide based gait on neurological examination. She rocks back and forth while sitting and shakes/flaps her hands frequently. Her demeanor is friendly and cooperative. System examination is unremarkable. Her cognitive and adaptive skills are within the moderate intellectual disability (ID) range (details see table).
Patient 2 :
was born by C-section at term due to previous Csection. Her initial weight was 3.2 kg (50th centile) and the head circumference was 35 cm (50th centile). Apgar scores were 9, 9 at 1 and 5 minutes. She was seizure-free until the age of six 1 Based on Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R) test. 2 Based on Stanford-Binet Intelligence Scales. Diagnosis of AtQ deficiency was confirmed in both sisters by elevated urinary α-AASA (7.1 mmol/mol creatinine and 1.4 mmol/mol creatinine in Patient 1 and 2 respectively (normal< 0.5). Molecular analysis of the AtQ (ALDH7A1) gene revealed compound heterozygousity for two known pathogenic missense mutations, c. 1195G>C (p. Glu399Gln) and c.1429G>C(p. Gly477Arg). 1, 6 the parents have not been tested.
DISCUSSION
the outcome of treated patients with PDE / AtQ deficiency is variable. Despite seizure control, 75% of patients have developmental delay and intellectual disability (ID). 7 In this report we demonstrate the intra-familial variability of intellectual long-term outcome. Both sisters have ID despite excellent seizure control. Although they share the same environment, type and onset of treatment, and ALDH7A1 mutations, they differ in their degrees of ID. the older sister is not able to live unassisted and meets criteria for moderate ID (IQ 35-55). the younger sister is able to live independently and work, and meets criteria for mild ID (IQ = 70-78). As in other patients described in the literature 8, 9 language development is affected in both patients. there are a few reports in the literature describing different outcomes in siblings with PDE. Ulvi et al, 2002 10 reported two sisters with PDE, one with mild intellectual disability at the age of eight years and the other with normal development at the age of one year. the course of the treatment was different between the two sisters and the younger sister still too young to predict long term intellectual development. Furthermore, in a series of 63 patients, ten families with multiple cases are reported with different clinical outcomes ranging from normal development to various degrees of intellectual disability. 7 While most of them had been started at different ages with pyridoxine treatment, the observation in our patients demonstrate that even despite early start of treatment in both patients, the outcomes may be variable.
It has been suggested that the earlier the onset of clinical seizures and the longer the delay in diagnosis and initiation of treatment, the worse is the prognosis for cognitive function. 7, 8, 11 On the other hand, patients treated as early as in the neonatal period had developmental delay and intellectual disability, whereas other patients with prolonged status epilepticus and later diagnosis had a normal IQ. 12 Prenatal treatment with high dose pyridoxine followed by postnatal treatment did not prevent poor cognitive outcome in two affected offspring, 13 while Bok et al, 2010 14 reported good developmental outcome after prenatal treatment in three children from two Dutch families.
In our patients the different age of seizure onset may be related to the outcomes. the older sister, who is more severely affected, had an onset of clinical seizures in the neonatal period, whereas in the milder affected younger sister seizure onset was at six weeks. In both siblings, treatment with vitamin B 6 was initiated at the time of clinical seizure onset, although PDE was not diagnosed until adulthood in both of them.
Although both sisters have increased urinary α-AASA excretion, the more affected older sister had a higher level, compared to her younger, less affected sister. this is consistent with the observation of Mills et al 2010 15 who reported three cases that had the highest α-AASA levels of their cohort and had the severest clinical phenotype. However, whether there is a significant correlation between biochemical and clinical phenotypes remains unclear. Our patients are compound heterozygotes for two pathogenic missense mutations in the ATQ (ALDH7A1) gene. Glu399Gln is the most common mutation observed in approximately 30% of mutated alleles. 15 It affects binding of cofactor (pyridoxal phosphate) and is thought to have a severe impact on enzyme activity while the other mutation is Gly477Arg has an effect on dimer formation. 16 Both patients had lactic acidemia, which resolved after administration of pyridoxine and thiamine. the pathophysiology of PDE is determined by secondary pyridoxal-5'phosphate (PLP) deficiency due to chemical inactivation of PLP via a condensation reaction with Piperideine-6-Carboxylate (P6C). 1 P6C is in equilibrium with AASA, the product that accumulates in PDE. Pyridoxine is a precursor of PLP. Such chemically induced PLP deficiency has major consequences on a multitude of pyridoxine (PLP) dependent enzyme activities, including enzyme reactions facilitating activation of glycogenolysis. 17 the observed lactic acidemia could therefore have been due to secondary PLP deficiency. Similar changes have been found in other patients with ATQ deficiency. 15 Despite the beneficial effect of pyridoxine on seizure activity, both patients have impaired cognitive outcome. While supplementation of pyridoxine aims at correction of PLP related pathophysiology, with the discovery of ATQ deficiency as the underlying cause, it has become clear that PDE is an organic aciduria affecting lysine degradation in the brain. Consequently, reduction of accumulating, potentially neurotoxic organic acids (AASA and related compounds) via a lysine-restricted diet may become an option for additional treatment. 5 Folinic acid responsiveness has been shown in a few cases 18 and although the pathophysiological background is unclear, folinic acid supplementation might be another way to improve outcomes in patients with PDE/AtQ deficiency. In summary our report highlights the variability of the natural history of the PDE ̸ ATQ deficiency even within the same family. International registries to accommodate more cases of PDE / ATQ deficiency will lead to a better understanding of the natural history and will facilitate well designed treatment and outcome studies.
